Syndax Pharmaceuticals Inc (SNDX) FinancialsSNDXSyndax Pharmaceuticals Inc

Evaluating the bottom line, Syndax Pharmaceuticals, Inc. maintains a gross margin of 95.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.95%, while the net margin is -67.82%. These profitability ratios, combined with a Return on Equity (ROE) of -255.93%, provide a clear picture of how effectively SNDX converts its operational activities into shareholder value.

In the context of the broader market, SNDX competes directly with industry leaders such as IMCR and KLRA. With a market capitalization of $1.21B, it holds a significant position in the sector. When comparing efficiency, SNDX's gross margin of 95.59% stands against IMCR's 99.06% and KLRA's N/A. Such benchmarking helps identify whether Syndax Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Syndax has shown substantial revenue growth, with Q2 2026 revenue increasing by 92% year-over-year to $72.8 million, but continues to report significant net losses.